US Business
J&J Says Covid-19 Vaccine Ingredient Batch Didn’t Meet Quality Standards
Johnson & Johnson says the batch didn’t advance to the filling and finish stages of its manufacturing process and that the quality lapse wouldn’t affect its ability to supply the U.S. with 100 million doses by the end of May.
